Use of agomelatine in obtaining medicaments intended for the...

Details Use of agomelatine in obtaining medicaments intended for the... Use of agomelatine in obtaining medicaments intended for the...

2011-05-24

2011-05-24

Padmanabhan, Sreeni (Department: 1627)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ketone doai

C514S617000, C514S622000, C514S557000, C514S507000, C514S510000, C514S643000, C514S646000, C514S650000, C514S658000

Reexamination Certificate

active

07947743

ABSTRACT:
The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, on its own or in association, in obtaining medicaments intended for the treatment of bipolar disorders, especially bipolar disorders of types I and II, and more especially bipolar disorders of type I.

REFERENCES:
patent: 5585118 (1996-12-01), Stoll
patent: 7122576 (2006-10-01), Plata-Salaman et al.
patent: 2006/0205754 (2006-09-01), Willigers
Chilman-Blair, “Agomelatine: antidepressant treatment of bipolar disorder melatonin agonist/5-HT2C antagonist”, Drugs of the Future, 2003, 28(1), pp. 7-13.
Alda, “Pharmacogenetics of lithium response in bipolar disorder”, Pharmacogenetics, 1999, 24(2), pp. 154-158.
Goldberg, J.F.,Current Psychiatry, 2010, 9 (5), 41-49.

Affiliated with

Also associated with

Rating

Use of agomelatine in obtaining medicaments intended for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of agomelatine in obtaining medicaments intended for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of agomelatine in obtaining medicaments intended for the... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2666202